An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Epidermal growth factor receptor (EGFR) mutations identify patients with lung cancer who derive benefit from kinase inhibitors. However, most patients eventually develop resistance, primarily due to the T790M second‐site mutation. Irreversible inhibitors (e.g., osimertinib/AZD9291) inhibit T790M‐EGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Mancini, Maicol, Gal, Hilah, Gaborit, Nadège, Mazzeo, Luigi, Romaniello, Donatella, Salame, Tomer Meir, Lindzen, Moshit, Mahlknecht, Georg, Enuka, Yehoshua, Burton, Dominick GA, Roth, Lee, Noronha, Ashish, Marrocco, Ilaria, Adreka, Dan, Altstadter, Raya Eilam, Bousquet, Emilie, Downward, Julian, Maraver, Antonio, Krizhanovsky, Valery, Yarden, Yosef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801506/
https://www.ncbi.nlm.nih.gov/pubmed/29212784
http://dx.doi.org/10.15252/emmm.201708076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801506/
https://www.ncbi.nlm.nih.gov/pubmed/29212784
http://dx.doi.org/10.15252/emmm.201708076

Ejemplares similares